Experimental cocktail targets Hard-to-Treat lymphoma
NCT ID NCT05626322
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a combination of three drugs—maplirpacept, tafasitamab, and lenalidomide—in 6 people with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy. The goal was to find a safe and effective dose of maplirpacept when added to the other two drugs. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maplirpacept (PF-07901801), tafasitamab, and lenalidomide
What this could lead to
If this combination works, it could offer a new treatment option for people with DLBCL who cannot have a stem cell transplant or CAR-T therapy.
What could go wrong
This is a very early, small trial (only 6 participants) that was terminated, so results are limited. The combination may cause serious side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dong-A University Hospital
Busan, Pusan-kwangyǒkshi, 49201, South Korea
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809, United States
-
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Yamagata University Hospital
Yamagata, 990-9585, Japan